Pacer Advisors Inc. Sells 9,218 Shares of Eli Lilly and Company (NYSE:LLY)

Pacer Advisors Inc. lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 13.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,799 shares of the company’s stock after selling 9,218 shares during the period. Pacer Advisors Inc.’s holdings in Eli Lilly and Company were worth $52,092,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Westwood Holdings Group Inc. lifted its position in Eli Lilly and Company by 5.4% in the 1st quarter. Westwood Holdings Group Inc. now owns 3,839 shares of the company’s stock worth $2,987,000 after buying an additional 196 shares during the last quarter. Guardian Capital LP increased its holdings in shares of Eli Lilly and Company by 3.0% in the first quarter. Guardian Capital LP now owns 921 shares of the company’s stock worth $717,000 after buying an additional 27 shares during the period. Linscomb Wealth Inc. lifted its stake in shares of Eli Lilly and Company by 0.5% in the 1st quarter. Linscomb Wealth Inc. now owns 3,389 shares of the company’s stock valued at $2,637,000 after acquiring an additional 17 shares during the last quarter. Steel Grove Capital Advisors LLC boosted its holdings in Eli Lilly and Company by 104.9% during the 1st quarter. Steel Grove Capital Advisors LLC now owns 795 shares of the company’s stock valued at $618,000 after acquiring an additional 407 shares during the period. Finally, Beck Capital Management LLC grew its position in Eli Lilly and Company by 1.9% during the 1st quarter. Beck Capital Management LLC now owns 8,824 shares of the company’s stock worth $6,865,000 after acquiring an additional 163 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on LLY. Morgan Stanley restated an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Bank of America dropped their price target on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Finally, BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,007.94.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Down 0.6 %

Shares of NYSE:LLY opened at $748.91 on Friday. The company has a market cap of $710.96 billion, a price-to-earnings ratio of 80.96, a PEG ratio of 2.76 and a beta of 0.43. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The company has a 50-day moving average price of $868.53 and a 200 day moving average price of $869.14.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the previous year, the business earned $0.10 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 20.4% on a year-over-year basis. As a group, equities research analysts predict that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.69%. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.